Search Results

MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.

MediWound Ltd. today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, March 21, 2024.

MediWound Ltd. announced today that recent clinical data from EscharEx ® Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).

MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

MediWound Ltd. today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.

MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound an additional $6.7 million in non-dilutive funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.

MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.